We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Regulatory System Falling Behind on Innovative Cancer Drugs, Study Says
EMA Regulatory System Falling Behind on Innovative Cancer Drugs, Study Says
Innovative cancer drugs are taking longer to get from clinical trials to EMA approval and availability for UK patients than more conventional treatments, the London-based Institute of Cancer Research (ICR) reported.